<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953730</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-JYL-05-01</org_study_id>
    <nct_id>NCT02953730</nct_id>
  </id_info>
  <brief_title>The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents</brief_title>
  <official_title>The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of the trail is to study the pharmacokinetics of Pegylated Recombinant Human
      Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>peak concentration(Cmax)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>elimination half life(t 1/2kel)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve(AUC)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≤18 years old, gender no limited.

          2. Patients with acute lymphoblastic leukemia diagnosed by bone marrow pathology or
             cytology.

          3. Plan to receive CAM (cyclophosphamide,cytarabine,6-MP)chemotherapy regimen.

          4. Previously not received radiotherapy.

          5. Karnofsky Performance Scores ( KPS)≥60.

          6. The expected survival time was ＞3 months.

          7. Neutropenia or agranulocytosis, no bleeding tendency.

          8. No significant cardiac dysfunction or metabolic disease.

          9. TBIL(total bilirubin ), ALT（alanine aminotransferase）,AST（glutamic-oxalacetic
             transaminase） ＜ 2.5×ULN（upper limit of normal）.

         10. BUN（blood urine nitrogen），Cr（creatinine），UA（uric acid）＜1.5×ULN.

         11. Written informed consent are acquired.

        Exclusion Criteria:

          1. With a history of systemic radiotherapy.

          2. Infection difficult to control, the body temperature ≥ 38℃.

          3. Other situation that investigators consider as contra-indication for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofan Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Xiaofan Zhu</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

